Prevalence and Risk Factors of Dermatoporosis in Patients Over 75 Years of Age Hospitalized in Reeducation (Dermatoporose)

The term dermatoporosis, by analogy to osteoporosis, was proposed by Professor Saurat to define all the manifestations linked to skin aging leading to fragility and skin failure. With age, the gradual disappearance of hyaluronic acid and its CD44 cell receptor leads to the degeneration of the extracellular matrix and then to the loss of the protective mechanical functions of the skin. It thus appears an alteration of the viscoelasticity of the skin. The most common skin manifestations of dermatoporosis are mainly located on the upper limbs. Several clinical manifestations characterize dermatoporosis: skin atrophy, senile purpura, stellate pseudo-scars, delayed healing and finally dissecting skin hematoma. There are 4 evolutionary stages of dermatoporosis described by Professor Saurat and by Doctor Kaya, in 2007: Stage 1: strong thinning of the skin with senile purpura and stellate pseudo-scars. Stage 2: manifestations of the previous stage and small, localized skin lacerations resulting from a cleavage between the dermis and the epidermis. Stage 3: more and larger skin lacerations with a noticeable delay in healing Stage 4: the progression of the lesions described above leads to the formation of dissecting skin hematomas which may progress to skin necrosis. (Saurat JH Dermatoporosis - the functional side of skin aging. Dermatology 2007 and Kaya G, dermatoporosis: A chronic cutaneous insufficiency / fragility syndrome. Clinicopathological features, mechanisms, prevention and potential treatments. Dermatology 2007).

A study by Mengeaud et al found a significant association between severe renal failure and dermatoporosis. Two studies, one in Toulouse and the other in Finland, looked at the prevalence and risk factors of dermatoporosis in patients over 60 years of age. The observational study on 202 patients over 60 years old in Toulouse shows a prevalence of 32%, with preferentially localization on the upper limbs. Stage 1 is the most common. Multivariate statistical analyzes show that dermatoporosis is significantly associated with the use of local and oral corticosteroids, anticoagulants, and chronic renal failure. On the other hand, it has not been shown to be associated with diabetes and the patient's sun exposure.Another study, dating from 2018 also found that kidney failure, taking antiaggregants and anticoagulants, corticosteroid therapy (local or systemic) are risk factors for dermatoporosis. However, no study has been carried out on a geriatric population, and the association between phototype, sun exposure and dermatoporosis has to our knowledge never been systematically investigated in the few studies conducted.

Study Overview

• Status: Completed
• Conditions: Dermatoporosis

Detailed Description

This study will allow us to know the prevalence and the risk factors of dermatoporosis in a poorly understood geriatric population. No study on the subject in patients over 75 years in the literature. We will be interested in collecting on the observations of patients recorded in Orbis (Initial medical assessment and evolution), in particular if the patient has chronic renal failure, is diabetic, has anticoagulants, antiaggregants or corticosteroids as a background treatment.

Main objective To assess the prevalence of dermatoporosis in patients over 75 years of age hospitalized in reeducation. Secondary objectives: Investigate risk factors for dermatoporosis - Evaluate the prevalence of complications of dermatoporosis

• Study Type: Observational
• Enrollment (Actual): 101

Contacts and Locations

Study Locations

• France
  • Paris, France, 75012
    • Hôpital Rotschild

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 75 years and older (Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Hospitalized patient in SSR over 75 years old.

Description

Inclusion Criteria:

• Hospitalized patient in SSR
• Over 75 years old patient

Exclusion Criteria:

• Refusal of participation

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Control
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Hospitalized patient in SSR geriatric service

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Presence or absence of dermatoporosis	Presence or absence of dermatoporosis in geriatric patients hospitalized in the CRH	From admission to discharge, up to 1 month

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Measurement of phototype	Measurement of phototype as a risk factors for dermatoporosis	At admission, Day 1
Childhood sun exposure Measurement of phototype	Childhood sun exposure as a risk factors for dermatoporosis	At admission, Day 1
Lifetime sun exposure Measurement of phototype	Lifetime sun exposure as a risk factors for dermatoporosis	At admission, Day 1
Complications of dermatoporosis:	Complications of dermatoporosis: dissecting hematoma, skin tear on clinical examination and in history	At admission, Day 1

Collaborators and Investigators

• Sponsor: Assistance Publique - Hôpitaux de Paris
• Investigators: Principal Investigator: Hester COLBOC, Assistance Publique - Hôpitaux de Paris

Study record dates

Study Major Dates

• Study Start (Actual): March 29, 2021
• Primary Completion (Actual): May 15, 2021
• Study Completion (Actual): May 15, 2021

Study Registration Dates

• First Submitted: May 14, 2021
• First Submitted That Met QC Criteria: October 22, 2021
• First Posted (Actual): October 25, 2021

Study Record Updates

• Last Update Posted (Actual): September 27, 2022
• Last Update Submitted That Met QC Criteria: September 26, 2022
• Last Verified: October 1, 2021

More Information

Terms related to this study

• Keywords: Skin aging; Dermatoporosis
• Other Study ID Numbers: APHP210431

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No